MSLN

Across TCGA pan-cancer cohorts, MSLN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MSLN data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MSLN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MSLN expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where MSLN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.646	0.915	.003	20	view →
LUAD	OS	Median	III,IV	0.223	0.670	.011	15	view →
HNSC	DFS	Median	All	0.721	0.518	.016	10	view →
UCEC	DFS	Tertile	All	0.948	0.824	.028	4	view →
LSCC	DFS	Median	All	0.899	0.976	.044	1	view →
CCRCC	OS	Median	II,III,IV	0.616	0.929	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MSLN–PDAC (DFS)

Open the PDAC breakdown →